SG Americas Securities LLC Takes $4.72 Million Position in Integra LifeSciences Holdings Corporation $IART

Key Points

• SG Americas Securities LLC bought a new stake of 380,229 shares in Integra LifeSciences during Q4, valued at about $4.72 million and representing roughly 0.49% ownership.
• Analyst sentiment is bearish overall — the stock has an average rating of "Reduce" and an average price target of $14.40, with recent downgrades including Citigroup cutting its target to $9 and issuing a sell.
• Integra is trading at $9.57 (12‑month range $8.70–$21.88, market cap ~$745.9M); it topped Q4 EPS and revenue estimates but reported a negative net margin, and guided FY 2026 EPS to 2.30–2.40 (consensus ~2.45).

SG Americas Securities LLC bought a new stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The firm bought 380,229 shares of the life sciences company's stock, valued at approximately $4,722,000. SG Americas Securities LLC owned 0.49% of Integra LifeSciences as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC grew its position in Integra LifeSciences by 55.3% in the third quarter. GAMMA Investing LLC now owns 2,565 shares of the life sciences company's stock valued at $37,000 after acquiring an additional 913 shares in the last quarter. Osaic Holdings Inc. lifted its position in shares of Integra LifeSciences by 36.6% during the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company's stock worth $51,000 after purchasing an additional 1,104 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Integra LifeSciences by 595.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company's stock valued at $98,000 after purchasing an additional 6,814 shares during the period. Amundi boosted its stake in shares of Integra LifeSciences by 17,193.8% in the second quarter. Amundi now owns 11,068 shares of the life sciences company's stock valued at $150,000 after purchasing an additional 11,004 shares during the period. Finally, State of Wyoming grew its holdings in Integra LifeSciences by 84.0% during the 2nd quarter. State of Wyoming now owns 12,953 shares of the life sciences company's stock valued at $159,000 after purchasing an additional 5,914 shares in the last quarter. 84.78% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on IART shares. Citigroup dropped their price target on shares of Integra LifeSciences from $11.00 to $9.00 and set a "sell" rating on the stock in a research note on Wednesday, March 11th. Wells Fargo & Company upgraded Integra LifeSciences to a "hold" rating in a research note on Wednesday, March 18th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Integra LifeSciences in a research report on Friday, March 27th. Finally, Wall Street Zen cut Integra LifeSciences from a "buy" rating to a "hold" rating in a research note on Saturday, March 7th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, Integra LifeSciences has an average rating of "Reduce" and an average price target of $14.40.

Integra LifeSciences Trading Up 1.6%

IART opened at $9.57 on Thursday. Integra LifeSciences Holdings Corporation has a 12-month low of $8.70 and a 12-month high of $21.88. The company has a debt-to-equity ratio of 1.66, a current ratio of 2.54 and a quick ratio of 1.46. The stock has a market capitalization of $745.89 million, a PE ratio of -1.42 and a beta of 1.06. The firm's fifty day moving average price is $10.50 and its 200 day moving average price is $12.33.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings data on Thursday, February 26th. The life sciences company reported $0.83 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.04. The company had revenue of $434.93 million during the quarter, compared to analyst estimates of $429.62 million. Integra LifeSciences had a negative net margin of 31.58% and a positive return on equity of 14.76%. The firm's revenue for the quarter was down 1.7% compared to the same quarter last year. During the same period last year, the business earned $0.97 EPS. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. As a group, research analysts expect that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.